Fact Sheet | October 2023

Early stage and preclinical testing services for Vaccines, Antivirals and Immunomodulators

Viroclinics-DDL, a Cerba Research Company, offers specialized preclinical services including testing of efficacy, safety, PK and (immune) toxicology of drugs, antibodies, vaccines and antivirals targeting infectious diseases.

Our in-house state of the art BSL-2 and BSL-3 facilities allow for complex experiments with highly pathogenic organisms. You can rely on a dedicated team of qualified laboratory technicians, expert scientists and study directors to ensure a proper design and execution of your preclinical study. Our specialized expertise will contribute to efficient product development and substantially to lower costs and risks.

Apart from the classical endpoints, we can also perform (histo) pathology. Pre-Clinical Services offer validated diagnostic assays to measure serological and cell mediated immune responses, validated assays to detect presence of viral and bacterial pathogens and measure pathogen load in different tissues. Assays can be tailor made to meet customer demand.



Key Facts & Figures

Facilities

18,000 ft² Preclinical Laboratory Area

- 18,000 ft2 preclinical laboratory area
- Dedicated GAP IV compliant
 Polio Facility >5000 ft²
- BSL3 Isolator rooms >1000 ft²
- BSL2 facilities

Laboratory Rooms

BSL2 and BSL3 Facilities

- 3 animal BSL2/SPF rooms
- 2 animal BSL3/Isolator rooms
- 3 virology/immunology BSL2 labs
- 1 clean cell line lab
- 3 rooms with PCR set-up
- 1 Histology lab
- 1 Polio essential facility including 3 processing rooms (animal rooms and analytical laboratory)

Animal Models and Disease Targets

Viroclinics-DDL has a solid track record of preclinical services and viral targets. Bacterial and oncological targets, as well as viral vectors used in the context of gene therapy are under development. We have extensive experience with multiple viral targets and animal models, such as mice, cotton rats, hamsters, ferrets, NHP, rabbits and cats.

.

Viral Targets

- H7N9 A/Influenza
- H5N1 A/Influenza
- (p)H1N1 A/Influenza
- H3N2 A/Influenza
- B/Influenza
- ...and more

- RSV (A and B)
- hMPV
- MERS Coronavirus
- SARS-CoV
- SARS-CoV-2
- Varicella Zoster Virus
- ...and more

- Measles Virus
- Dengue Virus
- Monkeypox Virus
- Rabies Virus
- Polio Viruses
- HSV
- CMV
- Parainfluenza
- Herpes Simplex and Virus
- Cytomegalovirus
 - ...and more



Key Benefits

One stop shop from permit application, to study design, to execution of preclinical experimentation and analysis of results

A solid scientific track record: 40+ publications in peer reviewed journals

Substantial reduction of development risk and cost

Uniquely expertized in (viral) infectious disease modelling


High-containment expertise

Customized models to tailor client needs, according to the 3R's

Rapid response time and clear day to day project management updates

Large biorepository of viral strains

40+ Highly Skilled Professionals





Our Track Record

471k

Samples processed within the last 3 years

116k

Genotypic Assays

300 +

Publications in peer-reviewed journals

30

182k

Phenotypic Assays

1600

Studies

99%

On Time Project Delivery

External QS Audits

International

Presence

Learn more about our contributions to vaccine and antiviral developments

Pre-Clinical Services | https://cerbaresearch.com/specialty-labbiomarker-services/pre-clinical-services/

